The problem with pediatric clinical trials; a crucial test of the FDA's independence

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: Aurobindo, major generic drug maker, will close a key U.S. production plant By Ed Silverman Adobe Aurobindo Pharma, one of the largest global producers of generic medicines, is closing its U.S. manufacturing facility next month. Read More STAT+: 'Harmful and wasteful': Many pediatric clinical trials end early and don't report results By Ed Silverman Adobe A new analysis of thousands of pediatric trials found one in 10 ended early, and many that were completed didn't report their results. Read More STAT+: Pfizer inks deal with UNICEF to supply Covid pill to poor countries, but advocates say it isn't enough By Ed Silverman Pfizer Pfizer has reached a deal with UNICEF to supply up to 4 million courses of its Covid-19 treatment to 95 low- and middle-income countries. Read More Sponsor content by Astellas Lessons for navigating the frontiers of medical science This is a defining decade for the future of healthcare. Right now, being at the forefront of drug development is an exciting place to be, but a challenging one. Not only are the stakes high — patients are waiting — but there are also often no precedents and no well-trodden paths to rely on. Learn more as Astellas' chief medical officer, Dr. Bernie Zeiher, shares his five key lessons for navigating the new frontiers of science. STAT+: An ALS therapy sets up a crucial test of the FDA's independence By Nicholas Florko Sarah Silbiger/Getty Images A high-profile experimental therapy for ALS is teeing up a crucial test of the Food and Drug Administration’s ability to withstand pressure. Read More Opinion: Covid-19 vaccine policy should be made by public health experts, not company executives By John P. Moore and Luciana L. Borio Joe Raedle/Getty Images Announcements by Pfizer and Moderna about adding a fourth dose of Covid-19 vaccines is adding to the confusion about their effectiveness. Read More Tuesday, March 22, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser